Join drug diversion investigators and pharmacy compliance specialists Russ Nix from Wolters Kluwer, Terri Vidals of Rxpert Solutions, and Allison Onkst of Diversion Forensics, for a practical discussion on interpreting drug diversion surveillance findings, separating meaningful indicators from routine variation, and identifying when to appropriately escalate to an investigation.
While technology can improve workflows, identify policy gaps, and support more consistent oversight, Russ, Terri, and Allison will explore how organizations can move beyond alerts, combining data insights with professional judgment to determine risk, prioritize concerns, and make informed investigative decisions.
Attendees will leave with relevant guidance, examples of effective practices seen across healthcare systems, and a clearer understanding of strategies to build stronger, more proactive diversion programs.
Learning Objectives
- Identify patterns, behavioral indicators, and documentation concerns that may suggest potential drug diversion or opportunities for process improvement.
- Describe how diversion professionals evaluate the totality of circumstances when determining whether surveillance findings warrant escalation.
- Explain the role of technology in strengthening diversion surveillance while recognizing the importance of expert analysis and human judgment in risk assessment.
- Discuss controlled substance waste practices as potential operational vulnerability and identify strategies to support compliance while reducing diversion risk.
- Evaluate best practices that contribute to proactive diversion surveillance programs, effective investigations, and continuous program improvement.